Movella Announces Xsens MTi Sensor Portfolio for Autonomous Machines and Edge AI Applications, With NVIDIA Jetson Platform Integration Capabilities
Movella, a leading provider of full-stack solutions for digitizing movement, today announced it has enhanced its Xsens MTi™ inertial sensor modules for autonomous machines and edge AI applications. The Xsens MTi sensors can be easily integrated with the NVIDIA Jetson™ platform for edge AI and robotics, offering full compatibility with the NVIDIA Jetson AGX Orin™, NVIDIA Jetson Orin™ NX, and NVIDIA Jetson Orin Nano™ system-on-modules.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716567003/en/
(Graphic: Business Wire)
The highly compact Xsens MTi sensors, also called “IMU”, are renowned for their high accuracy, reliability, and low latency, even under adverse conditions. They provide industrial-grade, real-time measurements of motion, orientation, and global position (GNSS), which are critical for navigating and controlling a wide range of mobile robots and smart automation applications, whether aerial, land-based, or subsea. Offering compatibility with the powerful AI capabilities of the NVIDIA Jetson platform, the Xsens MTi inertial sensors will help customers bring their intelligent and autonomous systems faster to the market.
The easy integration of NVIDIA Jetson Orin modules with Xsens MTi sensors will help enable more intelligent and efficient autonomous systems. Movella is a member of the NVIDIA Partner Network (NPN).
“The mobile robot market is undergoing massive growth and transformation as autonomous platforms such as autonomous mobile robots (AMRs) get widely adopted indoors and outdoors. Collaborating with NVIDIA on the Jetson platform integration has helped us advance the use of Xsens MTi sensors in mobile robotics and edge AI,” said Meindert Zeeuw, Director of the “Automation & Mobility” Line of Business at Movella. “The seamless integration of Xsens MTi’s precise and real-time data with NVIDIA Jetson’s accelerated computing capabilities will help innovators further in developing systems that can navigate, perceive, and interact with their environments with even more accuracy and agility.”
This integration highlights the momentum of the industrial inertial sensor market, particularly in logistics (autonomous robots, autonomous vehicles) and sea-based (ROV/AUV) applications. This segment has a projected 16% CAGR expected from 2021 to 2027, reaching an estimated value of USD 1.1 billion. Movella’s work underscores the industry’s rapid innovation and adoption of industrial inertial sensors, positioning the company to drive transformative advancements in intelligent automation within industrial applications.
About Movella
Movella is a leading full-stack provider of sensors, software, and analytics that enable the digitization of movement. Movella serves the automation & mobility, entertainment and health & sports markets. Movella's innovations enable customers to capitalize on the value of movement by transforming data into meaningful and actionable insights. Partnering with leading global brands such as ABB Marine, Hewlett Packard, Kongsberg, Clearpath Robotics, Toyota, Siemens, Electronic Arts, EPIC Games, 20th Century Studios, Netflix and more than 500 sports organizations, Movella is creating extraordinary outcomes that move humanity forward. To learn more, please visit www.movella.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716567003/en/
Contacts
Amitabh Sharan
amitabh.sharan@movella.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom